The cell cycle of pathogenic fungi: target for drugs.
Life-threatening fungal infections are becoming more frequent and involve a greater variety of strains, many of which are drug-resistant. Both public research organisations and the pharmaceutical industry are committed to the development of new drugs to satisfy this increasing medical need. The approach described here exemplifies the efforts directed towards the discovery of drugs which are active against novel targets, exemplified by the cell-cycle regulator, Civ1.
Aventis Pharma, Infectious Diseases Group, 102 route de Noisy, F93235 Romainville, France.
Florence
F
Bordon-Pallier
Nathalie
N
Jullian
Jean-Luc
JL
Haesslein
D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology*; D018797:Cell Cycle Proteins / Q000187:drug effects* / Q000378:metabolism; D018844:Cyclin-Dependent Kinases; D004353:Drug Evaluation, Preclinical; D025141:Drug Resistance, Fungal / Q000187:drug effects / Q000502:physiology; D005658:Fungi / Q000187:drug effects* / Q000201:enzymology* / Q000472:pathogenicity; D006801:Humans; D015394:Molecular Structure; D009181:Mycoses / Q000188:drug therapy* / Q000201:enzymology* / Q000503:physiopathology; D017346:Protein Serine-Threonine Kinases / Q000187:drug effects / Q000378:metabolism; D017386:Sequence Homology, Amino Acid; D000095043:Cyclin-Dependent Kinase-Activating Kinase
D000935:Antifungal Agents; D018797:Cell Cycle Proteins; D017346:Protein Serine-Threonine Kinases; D018844:Cyclin-Dependent Kinases; D000095043:Cyclin-Dependent Kinase-Activating Kinase